Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma.
Dogan
Erkan
E
Aksoy
Sercan
S
Arslan
Cagatay
C
Dede
Didem S
DS
Altundag
Kadri
K
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced* / Q000517:prevention & control*; D011379:Prognosis; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib